Get the Daily Brief
Latest Biotech News
Oncology – immunotherapy dosing model challenges PET-style assumptions
A translational modelling study questions a core assumption behind pembrolizumab dosing: that saturating the PD-1 receptor on T cells predicts immune activation. Published in the British Journal...
Immuno-oncology – early clinical signal in small cell lung cancer
Tarlatamab’s subcutaneous formulation produced a safety and early activity readout in extensive-stage small cell lung cancer (ES-SCLC) during the Phase 1b DeLLphi-308 study. Presented at the...
Oncology – PD-L1-high phase 3 setback for ADC plus checkpoint inhibitor
A closely watched Phase 3 trial failed to show added benefit for combining the antibody-drug conjugate sacituzumab govitecan with pembrolizumab in first-line PD-L1–high metastatic lung cancer. The...
Oncology – new image-guided ablation approach for children
A review in Pediatric Radiology highlights how image-guided percutaneous ablation is increasingly reshaping care for children with solid tumors—shifting treatment away from traditional surgery in...
Biomarkers & diagnostics – real-world evidence for IgA nephropathy treatment
A new real-world study suggests that Nefecon (targeted-release budesonide) can reduce proteinuria and help preserve kidney function in primary IgA nephropathy, including in patients who start with...
Neuroscience – Alzheimer’s blood and spinal markers sequence plaques
Blood and spinal fluid profiling in Alzheimer’s disease appears to track brain pathology in a strict sequence, tying circulating and cerebrospinal measurements to amyloid and neurodegeneration...
Oncology – large-scale canine cancer molecular subtyping
A landmark RNA profiling effort split canine splenic hemangiosarcoma into three molecularly actionable subtypes, showing that tumors arising in the same dog can be biologically distinct at the...
Hematology/Oncology therapeutics – outpatient delivery consensus for CPX-351
A new international consensus effort established detailed guidance on delivering CPX-351, the liposomal formulation of cytarabine and daunorubicin, outside inpatient hospital wards for...
Clinical science – major dataset on treatment-free benefit mismatch in colorectal immunotherapy economics
A health-economics analysis found that nivolumab plus ipilimumab may deliver more quality-adjusted life years at lower total cost than pembrolizumab for metastatic MSI-high or mismatch...
FDA approval for spinal muscular atrophy muscle-loss indication
The FDA approved Scholar Rock’s first therapy specifically targeting muscle loss in spinal muscular atrophy, Isembyld, expanding options beyond SMN2-targeted care. The approval covers adults and...
Small cell lung cancer: subcutaneous tarlatamab safety and early signals
New phase 1b DeLLphi-308 data presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul reported safety and early antitumor activity for...
Small cell lung cancer: dosing interval flexibility with tarlatamab
A randomized phase 2 DeLLphi-309 analysis presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul suggested that longer gaps between...
Clinical trial setback: sacituzumab govitecan plus pembrolizumab in PD-L1 high metastatic lung cancer
A closely watched phase 3 trial in PD-L1–high metastatic lung cancer delivered a setback for an antibody-drug combination strategy. Sacituzumab govitecan, an antibody-drug conjugate, failed to...
Real-world safety/efficacy: Nefecon in IgA nephropathy
A real-world study reported that Nefecon, the targeted-release formulation of budesonide, reduced proteinuria and helped preserve kidney function in patients with primary IgA nephropathy,...
Antisense vs. biology: receptor occupancy fails to predict pembrolizumab immune activation
A translational modeling study challenged a core assumption behind pembrolizumab dosing. The work, published in the British Journal of Cancer, reports that receptor occupancy of PD-1 fails to...
Oncology immunology mechanism: T cell activation inside tumors can eliminate tumors independent of specificity
A new study is attracting attention for suggesting that intratumoral T-cell activation can drive tumor elimination even without T-cell antigen specificity. The report’s central claim is that...
Big-tech oncology imaging/AI: PET imaging to confirm checkpoint inhibitor drug delivery to tumors
A British Journal of Cancer study evaluated whether PET imaging can indicate if immunotherapy drugs actually reach their tumor targets. The approach addresses a practical clinical gap: most...
Oncology safety signal: hand-foot syndrome risk mapped across FDA safety reports
A large FDA analysis mapped the risk of chemotherapy-induced hand-foot syndrome, identifying which anticancer medicines are most frequently implicated. The dataset compiles safety reports over...
Biotech deal dynamics: Solstice $225M neoadjuvant CTLA-4 program
Solstice announced a $225M funding-supported advancement of a next-generation CTLA-4 asset into neoadjuvant treatment, following a capital-led syndicate backing the NewCo. The financing package...
Regulatory approvals
The FDA has approved Scholar Rock’s myostatin-inhibition therapy, Isembyld, for spinal muscular atrophy (SMA) in adults and children 2 years and older who are already receiving SMN2-targeting...